Darbepoetin
| Drug Category | Drug | IHD Dosing | Administration Timing Around HD Session |
|---|---|---|---|
| Anemia Medications | Darbepoetin | initial: 0.45mcg/kg/wk | Administer Anytime During HD |
Molecular Weight (Da) | Excreted Unchanged (%) | Normal Half-Life (Hours) | ESRD Half-Life (Hours) | Plasma Protein Binding (%) | Volume of Distribution (L/kg) | Dialytic Plasma Clearance (ml/min) | % Dialyzed |
|---|---|---|---|---|---|---|---|
| 37100 | N/A | N/A | IV: 25.3; SC: 48 | N/A | 0.06 | N/A | No (high/low fux) |
References:
- Allon M, Kleinman K, Walczyk M et al. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. Clinical pharmacology and therapeutics 2002; 72(5), 546-55.
- DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00012
- McMahon L, Chester K, Walker R. Effects of different dialysis membranes on serum concentrations of epoetin alfa, darbepoetin alfa, enoxaparin, and iron sucrose during dialysis. American Journal of Kidney Diseases 2004; 44(3), 509-516.